P2RY12 and ischemia: However, given the higher risk of ischemia associated with clopidogrel use in patients with a LOF allele, and the clear cardiovascular benefits of using ticagrelor, it is recommended that clinicians should increase the weight of genetics when choosing P2Y12 inhibitors.